<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04841096</url>
  </required_header>
  <id_info>
    <org_study_id>SIL-30013-III-20(1)</org_study_id>
    <nct_id>NCT04841096</nct_id>
  </id_info>
  <brief_title>Oral Combination of Glimepiride/Vildagliptin/Metformin in Patients With T2D and Dual Treatment Failure</brief_title>
  <official_title>Efficacy and Safety of the Oral Combined Therapy Glimepiride / Vildagliptin / Metformin in Patients With Type 2 Diabetes With Dual Treatment Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratorios Silanes S.A. de C.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratorios Silanes S.A. de C.V.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase IIIb, randomized, multicenter, double-blind, prospective study to evaluate the efficacy&#xD;
      and safety of a daily fixed-dose combination of glimepiride / vildagliptin / metformin in&#xD;
      patients with type 2 diabetes with a history of dual treatment failure and combined or&#xD;
      individual oral antidiabetics with SGLT2 / Metformin, Biguanide / Sulfonylurea, Sulfonylurea&#xD;
      / iDPP4 or Biguanide / iDPP4. To evaluate the changes in the percentage of HbA1c at 3 and 6&#xD;
      months with regard to their baseline measurement.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To achieve glycemic control goals, a combination of medications with complementary mechanisms&#xD;
      of action, with fasting and postprandial effects, may be required to achieve and maintain&#xD;
      clinically acceptable glycemic control in some patients. A fixed combination of two or more&#xD;
      therapeutic agents with complementary mechanisms of action makes it possible to optimize&#xD;
      compliance and adherence to treatment among patients with T2D because it is administered once&#xD;
      a day with the same efficacy of the separate components, but with fewer gastrointestinal&#xD;
      effects. This is reflected in a reduction in HA1c and a lower evolution to long-term&#xD;
      complications of T2D. Phase IIIb, randomized, multicenter, double-blind, prospective study to&#xD;
      evaluate the efficacy and safety of a daily fixed-dose combination of glimepiride /&#xD;
      vildagliptin / metformin in patients with type 2 diabetes with a history of dual treatment&#xD;
      failure and combined or individual oral antidiabetics with SGLT2 / Metformin, Biguanide /&#xD;
      Sulfonylurea, Sulfonylurea / iDPP4 or Biguanide / iDPP4.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare changes in HbA1</measure>
    <time_frame>baseline, 3 and 6 months of treatment</time_frame>
    <description>Mean change in HbA1c</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients who change their HbA1c concentration</measure>
    <time_frame>baseline, 3 and 6 months of treatment</time_frame>
    <description>Proportion of patients who change their HbA1c by at least 1 percent</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean difference change between groups in HbA1c concentration</measure>
    <time_frame>baseline, 3 and 6 months of treatment</time_frame>
    <description>Difference greater than 0.3 between group A and B HbA1c concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean glucose change</measure>
    <time_frame>baseline, 3 and 6 months of treatment</time_frame>
    <description>Compare changes in glucose between baseline, 3 and 6 months of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events and reactions</measure>
    <time_frame>baseline, 3 and 6 months of treatment</time_frame>
    <description>Description of al the adverse events and reactions presented during the study</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">172</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Group A: Glimepiride (2mg) / Vildagliptin (50mg) / Metformin (1000mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablets, orally, once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: Glimepiride (2mg) / Vildagliptin (50mg) / Metformin (1000mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablets, orally, once a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glimepiride / Vildagliptin / Metformin (2 mg/ 50 mg/ 1000 mg)</intervention_name>
    <description>Take one tablet of the prescribed dose of the investigational drug by mouth, preferably with food and in the morning</description>
    <arm_group_label>Group A: Glimepiride (2mg) / Vildagliptin (50mg) / Metformin (1000mg)</arm_group_label>
    <other_name>G/V/M (1)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glimepiride / Vildagliptin / Metformin (4 mg/ 50 mg/ 1000 mg)</intervention_name>
    <description>take one tablet of the prescribed dose of the investigational drug by mouth, preferably with food and in the morning</description>
    <arm_group_label>Group B: Glimepiride (2mg) / Vildagliptin (50mg) / Metformin (1000mg)</arm_group_label>
    <other_name>G/V/M (2)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or Female.&#xD;
&#xD;
          -  Age &gt;18 years old at the beginning of the study.&#xD;
&#xD;
          -  Diagnosis of type 2 diabetes prior to the start of the study.&#xD;
&#xD;
          -  Therapeutic failure to a dual treatment with SGLT2 / Metformin, Biguanide /&#xD;
             Sulfonylurea, Sulfonylurea / iDPP4, Biguanide / iDPP4.&#xD;
&#xD;
          -  HbA1c ≥ 7.5% and ≤ 11% during screening tests.&#xD;
&#xD;
          -  Women of childbearing potential using a contraceptive method (barrier, oral hormonal,&#xD;
             injectable, subdermal) or naturally or surgically sterile in menopause.&#xD;
&#xD;
          -  Subject agree to participate in the study and give informed consent in writing.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The drug is contraindicated for medical reasons.&#xD;
&#xD;
          -  History of Type 1 Diabetes Mellitus.&#xD;
&#xD;
          -  History of metabolic complications such as ketoacidosis or nonketotic hyperosmolar&#xD;
             state.&#xD;
&#xD;
          -  History of gastric bariatric surgery or gastric band in the last year.&#xD;
&#xD;
          -  History of drug or alcohol abuse in the past year.&#xD;
&#xD;
          -  Body Mass Index &lt;20 kg/m2 and &gt;40 kg/m2.&#xD;
&#xD;
          -  Acute or severe renal dysfunction (glomerular filtration &lt;30 ml / min / 1.72 m2).&#xD;
&#xD;
          -  History of chronic liver disease or ALT and / or AST ≥3 times the normal upper limit&#xD;
             and / or Total Bilirubin&gt; 2.5 times the upper limit of normal, or GGT ≥3 times the&#xD;
             upper limit of normal.&#xD;
&#xD;
          -  Pregnant and / or lactating women.&#xD;
&#xD;
          -  The patient is participating in another clinical study involving an investigational&#xD;
             treatment or participated in one in the previous 4 weeks.&#xD;
&#xD;
          -  At medical criteria, a disease that affects the prognosis and prevents outpatient&#xD;
             management, for example, but not restricted to: end-stage cancer, kidney, heart,&#xD;
             respiratory or liver failure, mental illness, with scheduled surgical or hospital&#xD;
             procedures.&#xD;
&#xD;
          -  Be a patient with a working relationship with the main researcher or the research&#xD;
             center or deprived of liberty.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Salvador Pérez Jaime, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro de Investigación Médica Aguascalientes (Red OSMO)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan A Becerra Hernández, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro de Investigación y Avances Médicos Especializados (Red OSMO)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ana L Flores Barranco, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oaxaca Site Management Organization SC. (Red OSMOS)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Abraham S Álvarez, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oncológico Potosino (Red OSMO)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Victor C Bohórquez López, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mérida Investigación Clínica (Red OSMO)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jorge A González, PhD</last_name>
    <phone>5254883785</phone>
    <phone_ext>3761</phone_ext>
    <email>jogonzalez@silanes.com.mx</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yulia Romero-Antonio, B.S.</last_name>
    <phone>5554883700</phone>
    <phone_ext>3777</phone_ext>
    <email>yromero@silanes.com.mx</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centro de Investigación y Avances Médicos Especializados</name>
      <address>
        <city>Cancún</city>
        <state>Quintana Roo</state>
        <zip>77506</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <contact>
      <last_name>Juan A Becerra Hernández, M.D</last_name>
      <phone>998 138 2821</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mérida Investigación Clínica</name>
      <address>
        <city>Merida</city>
        <state>Yucatan</state>
        <zip>97125</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <contact>
      <last_name>Victor C Bohórquez López, M.D</last_name>
      <phone>999 688 9735</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Investigación Médica Aguascalientes</name>
      <address>
        <city>Aguascalientes</city>
        <zip>20116</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <contact>
      <last_name>Salvador Pérez Jaime, M.D</last_name>
      <phone>449 994 9458</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oaxaca Site Management Organization SC.</name>
      <address>
        <city>Oaxaca</city>
        <zip>68000</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <contact>
      <last_name>Ana L Flores Barranco, M.D</last_name>
      <phone>951 514 7056</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncológico Potosino</name>
      <address>
        <city>San Luis Potosí</city>
        <zip>78250</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <contact>
      <last_name>Abraham S Álvarez, M.D</last_name>
      <phone>444 139 7700</phone>
    </contact>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020 Jan;43(Suppl 1):S14-S31. doi: 10.2337/dc20-S002. Review.</citation>
    <PMID>31862745</PMID>
  </reference>
  <reference>
    <citation>Cahn A, Raz I, Kleinman Y, Balicer R, Hoshen M, Lieberman N, Brenig N, Del Prato S, Cefalu WT. Clinical Assessment of Individualized Glycemic Goals in Patients With Type 2 Diabetes: Formulation of an Algorithm Based on a Survey Among Leading Worldwide Diabetologists. Diabetes Care. 2015 Dec;38(12):2293-300. doi: 10.2337/dc15-0187. Epub 2015 Oct 30.</citation>
    <PMID>26519337</PMID>
  </reference>
  <reference>
    <citation>Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004 May;27(5):1218-24. Review.</citation>
    <PMID>15111553</PMID>
  </reference>
  <reference>
    <citation>Rubin RR. Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus. Am J Med. 2005 May;118 Suppl 5A:27S-34S. Review.</citation>
    <PMID>15850551</PMID>
  </reference>
  <reference>
    <citation>Khunti K, Kosiborod M, Ray KK. Legacy benefits of blood glucose, blood pressure and lipid control in individuals with diabetes and cardiovascular disease: Time to overcome multifactorial therapeutic inertia? Diabetes Obes Metab. 2018 Jun;20(6):1337-1341. doi: 10.1111/dom.13243. Epub 2018 Mar 11. Review.</citation>
    <PMID>29405543</PMID>
  </reference>
  <reference>
    <citation>Orozco-Beltrán D, Mata-Cases M, Artola S, Conthe P, Mediavilla J, Miranda C. [Adherence of Type 2 Diabetes Mellitus approach: Current situation and possible solutions]. Aten Primaria. 2016 Jun-Jul;48(6):406-20. doi: 10.1016/j.aprim.2015.09.001. Epub 2016 Jan 13. Spanish.</citation>
    <PMID>26775266</PMID>
  </reference>
  <reference>
    <citation>Garber AJ, Handelsman Y, Grunberger G, Einhorn D, Abrahamson MJ, Barzilay JI, Blonde L, Bush MA, DeFronzo RA, Garber JR, Garvey WT, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Perreault L, Rosenblit PD, Samson S, Umpierrez GE. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2020 EXECUTIVE SUMMARY. Endocr Pract. 2020 Jan;26(1):107-139. doi: 10.4158/CS-2019-0472.</citation>
    <PMID>32022600</PMID>
  </reference>
  <reference>
    <citation>Lukashevich V, Del Prato S, Araga M, Kothny W. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea. Diabetes Obes Metab. 2014 May;16(5):403-9. doi: 10.1111/dom.12229. Epub 2013 Dec 2.</citation>
    <PMID>24199686</PMID>
  </reference>
  <reference>
    <citation>Maruthur NM, Tseng E, Hutfless S, Wilson LM, Suarez-Cuervo C, Berger Z, Chu Y, Iyoha E, Segal JB, Bolen S. Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis. Ann Intern Med. 2016 Jun 7;164(11):740-51. doi: 10.7326/M15-2650. Epub 2016 Apr 19. Review.</citation>
    <PMID>27088241</PMID>
  </reference>
  <reference>
    <citation>Dennis JM, Henley WE, Weedon MN, Lonergan M, Rodgers LR, Jones AG, Hamilton WT, Sattar N, Janmohamed S, Holman RR, Pearson ER, Shields BM, Hattersley AT; MASTERMIND Consortium. Sex and BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating Stratification Using Routine Clinical and Individual Trial Data. Diabetes Care. 2018 Sep;41(9):1844-1853. doi: 10.2337/dc18-0344. Epub 2018 Aug 2.</citation>
    <PMID>30072404</PMID>
  </reference>
  <reference>
    <citation>Bianchi C, Daniele G, Dardano A, Miccoli R, Del Prato S. Early Combination Therapy with Oral Glucose-Lowering Agents in Type 2 Diabetes. Drugs. 2017 Mar;77(3):247-264. doi: 10.1007/s40265-017-0694-4. Review.</citation>
    <PMID>28155046</PMID>
  </reference>
  <reference>
    <citation>U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes. 1995 Nov;44(11):1249-58. Erratum in: Diabetes 1996 Nov;45(11):1655.</citation>
    <PMID>7589820</PMID>
  </reference>
  <reference>
    <citation>Levy J, Atkinson AB, Bell PM, McCance DR, Hadden DR. Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study. Diabet Med. 1998 Apr;15(4):290-6.</citation>
    <PMID>9585393</PMID>
  </reference>
  <reference>
    <citation>Benford M, Milligan G, Pike J, Anderson P, Piercy J, Fermer S. Fixed-dose combination antidiabetic therapy: real-world factors associated with prescribing choices and relationship with patient satisfaction and compliance. Adv Ther. 2012 Jan;29(1):26-40. doi: 10.1007/s12325-011-0096-z. Epub 2012 Jan 12.</citation>
    <PMID>22246944</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 6, 2021</study_first_submitted>
  <study_first_submitted_qc>April 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2021</study_first_posted>
  <last_update_submitted>June 8, 2021</last_update_submitted>
  <last_update_submitted_qc>June 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 diabetes</keyword>
  <keyword>Combine therapy</keyword>
  <keyword>Hypoglycemic agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Glimepiride</mesh_term>
    <mesh_term>Vildagliptin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

